NewmontvsUSANA Health Sciences

NEM and USNA stock compared: price, dividend, valuation and results, from SEC filings.

Newmont (NEM) has a market value of $121B and USANA Health Sciences (USNA) $250M. Over the last year, with dividends, NEM moved +27.9% and USNA -29.3%. Dividend yield: NEM 0.93%, USNA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    NEM$121B

    USNA$250M

    NEM is 483 times USNA

  • Revenue, 12 months

    NEM$26.6B

    USNA$906M

    NEM is 29 times USNA

  • Net income, 12 months

    NEM$9.2B

    USNA-$21M

  • Operating margin

    NEM–

    USNA-0.4%

  • ROIC

    NEM22.0%

    USNA-0.6%

    22.6 points apart

  • P/E

    NEM13.1

    USNA–

  • Dividend yield

    NEM0.9%

    USNA0.0%

    0.9 points apart

  • 5-year return

    NEM+119.4%

    USNA-86.9%

    206.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

NEM+119.4%

USNA-86.9%

010020020222023202420252026
Returns by period
PeriodNEMWith dividendsUSNAWith dividends
1 year since November 14, 2025+27.9%Price +26.7%-29.3%Price -29.3%
3 years since November 17, 2023+224.2%+48.0% a yearPrice +206.1%-70.6%-33.5% a yearPrice -70.6%
5 years since November 16, 2021+119.4%+17.0% a yearPrice +91.4%-86.9%-33.4% a yearPrice -86.9%
10 years since November 17, 2016+335.3%+15.8% a yearPrice +240.2%-78.3%-14.2% a yearPrice -78.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

NEMNewmontUSNAUSANA Health Sciences

Valuation

NEMUSNA
Valuation
Price$111.26$13.57
Market value$121B$250M
Enterprise value (EV)$117B$72M
P/E13.1–
P/E, 5-year median15.616.3
P/B3.40.5
EV/EBIT8.4–
Free cash flow yield8.3%11.8%

Results and growth

NEMUSNA
Results and growth
Revenue, 12 months$26.6B$906M
Net income, 12 months$9.2B-$21M
Free cash flow, 12 months$10.1B$30M
Earnings per share, 12 months$8.60-$1.14
Revenue growth, year on year21.3%8.3%
Revenue growth a year, past+14.5%over 5 years-4.0%over 5 years
EPS growth a year, past+12.7%over 5 years-37.0%over 5 years

Margins and returns on capital

NEMUSNA
Margins and returns on capital
Gross margin69.2%77.3%
Operating margin–-0.4%
Net margin34.7%-2.3%
ROIC22.0%-0.6%
ROE26.7%-4.0%

Balance sheet

NEMUSNA
Balance sheet
Cash$8.8B$179M
Total debt$5.1B$18M
Net debt / EBITDA-0.2-6.2
Interest cover–-9.4×

Dividends and buybacks

NEMUSNA
Dividends and buybacks
Dividend yield0.9%–
Dividend per share, 12 months$1.03–
Dividend growth a year, past––
Buyback yield1.9%11.0%
Shareholder yield2.8%11.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: NEM or USNA

Didn't find what you were looking for?

Ask us
Which is bigger, Newmont or USANA Health Sciences?

By market value, Newmont ($121B) is about 483.3 times USANA Health Sciences ($250M), at today's prices.

How did NEM and USNA stock do over the last 10 years?

Since November 17, 2016, NEM's price moved +240.2% and USNA's -78.3%. With dividends: NEM +335.3% (+15.8% a year), USNA -78.3% (-14.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, NEM or USNA?

The dividend yield at today's price is 0.93% for Newmont and none for USANA Health Sciences. Over the last twelve months they paid $1.03 and – per share.

Which has the higher profit margins, Newmont or USANA Health Sciences?

Over the last twelve months, the net margin was 34.7% for Newmont and -2.3% for USANA Health Sciences, and the operating margin – and -0.4%. Revenue was $26.6B and $906M.

Which is the better investment, Newmont or USANA Health Sciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.